Comparison of patients who are employed or unemployed in this study. Values are mean ± SD unless otherwise specified.
| Characteristics | No. Patients* | Total Patients, n = 1274 | Employed, n = 451 | Unemployed, n = 823 |
|---|---|---|---|---|
| Age, yrs | 1274 | 62.2 ± 13.7 | 53.5 ± 13.1 | 67.0 ± 11.5 |
| Female, n (%) | 1274 | 1092 (85.7) | 361 (80.0) | 731 (88.8) |
| RA disease duration, n (%) | 1274 | |||
| ≤ 3 yrs | 112 (8.8) | 46 (10.2) | 66 (8.0) | |
| > 3 and ≤ 5 yrs | 135 (10.6) | 52 (11.5) | 83 (10.1) | |
| > 5 yrs | 1027 (80.6) | 353 (78.3) | 674 (81.9) | |
| RF positivity, n (%) | 1254 | 988 (78.8) | 346 (77.1) | 642 (79.8) |
| Comorbidities positivity, n (%) | 1274 | 411 (32.3) | 100 (22.2) | 311 (37.8) |
| Cardiovascular disease | 63 (4.9) | 9 (2.0) | 54 (6.6) | |
| Cerebrovascular disease | 14 (1.1) | 2 (0.4) | 12 (1.5) | |
| Hypertension | 133 (10.4) | 29 (6.4) | 104 (12.6) | |
| Diabetes | 77 (6.0) | 18 (4.0) | 59 (7.2) | |
| Pulmonary disease | 156 (12.2) | 40 (8.9) | 116 (14.1) | |
| Chronic kidney disease | 34 (2.7) | 6 (1.3) | 28 (3.4) | |
| Malignancy | 79 (6.2) | 16 (3.5) | 63 (7.7) | |
| TJC28 | 1274 | 0.8 ± 2.2 | 0.7 ± 1.7 | 0.9 ± 2.5 |
| SJC28 | 1274 | 1.1 ± 2.4 | 0.9 ± 2.2 | 1.1 ± 2.5 |
| Physician VAS, /10 cm | 1274 | 7.1 ± 11.3 | 6.7 ± 11.4 | 7.4 ± 11.3 |
| Pain VAS, /10 cm | 1273 | 20.0 ± 22.8 | 14.8 ± 17.7 | 22.8 ± 24.8 |
| GH VAS, /10 cm | 1264 | 20.7 ± 23.0 | 15.0 ± 18.1 | 23.9 ± 24.8 |
| HAQ | 1263 | 0.61 ± 0.77 | 0.33 ± 0.47 | 0.77 ± 0.86 |
| DAS28-ESR | 1251 | 2.6 ± 1.2 | 2.6 ± 1.1 | 2.8 ± 1.2 |
| SDAI | 1256 | 4.9 ± 6.5 | 3.9 ± 5.8 | 5.4 ± 6.9 |
| CDAI | 1261 | 4.6 ± 6.4 | 3.7 ± 5.6 | 5.1 ± 6.8 |
| EQ-5D | 1165 | 0.77 ± 0.20 | 0.82 ± 0.18 | 0.75 ± 0.21 |
| ESR, mm/h | 1264 | 25.3 ± 23.6 | 19.8 ± 18.8 | 28.3 ± 25.5 |
| CRP, mg/dl | 1272 | 0.37 ± 1.29 | 0.27 ± 0.87 | 0.43 ± 1.46 |
| MMP-3, ng/ml | 1249 | 65.6 ± 90.2 | 58.7 ± 82.1 | 69.4 ± 94.2 |
| Medication, n (%) | ||||
| Methotrexate | 1271 | 833 (65.5) | 337 (74.7) | 496 (60.5) |
| Other DMARD | 1274 | 248 (19.5) | 68 (15.1) | 180 (21.9) |
| Biologic agents | 1274 | 730 (57.3) | 266 (59.0) | 464 (56.4) |
| Oral corticosteroid | 1274 | 229 (18.0) | 52 (11.5) | 177 (21.5) |
| Anti-osteoporotic drug | 1274 | 271 (21.3) | 52 (11.5) | 219 (26.6) |
| WPAI test, % | ||||
| Work time missed due to RA | 426 | N/A | 1.7 ± 9.1 | N/A |
| Impairment while working due to RA | 438 | N/A | 15.1 ± 21.5 | N/A |
| Activity impairment due to RA | 1248 | 23.7 ± 26.7 | 17.5 ± 21.8 | 27.2 ± 28.5 |
↵* No. patients with available data. RA: rheumatoid arthritis; RF: rheumatoid factor; TJC28: tender joint count in 28 joints; SJC28: swollen joint count in 28 joints; VAS: visual analog scale; GH: general health; HAQ: Health Assessment Questionnaire; DAS28: Disease Activity Score in 28 joints; ESR: erythrocyte sedimentation rate: SDAI, Simple Disease Activity Index; CDAI: Clinical Disease Activity Index; CRP: C-reactive protein; MMP-3: matrix metalloproteinases 3; DMARD: disease-modifying antirheumatic drugs; WPAI: Work Productivity and Activity Impairment questionnaire; N/A: not applicable.